The RAS Chase: Gaining Ground Against the Toughest Oncogene

Marijke Vroomen Durning, RN
Published: Tuesday, May 24, 2016
Philip A. Philip, MD, PhD

Philip A. Philip, MD, PhD

Nearly 35 years after its discovery as the first human oncogene, RAS remains a frustrating target in anticancer therapy even as knowledge about the molecular drivers of malignancies continues to expand at a rapid pace. Thus far, no therapies aimed directly at RAS mutations have been developed.


From Rats to Humans

The observation that RAS genes could cause cancer was initially discovered in rat sarcomas; hence the name, RA for rat and S for sarcoma. These genes were later identified in humans in 1982. RAS is a family of oncogenes that are present in all cells in the body and were the first oncogenes identified in human cancer cells.1 Oncogenes work as an on/off switch for cell division, and RAS mutations affect this switch, not allowing the cells to switch off and causing them to grow uncontrollably, leading to the development of cancer.

Initiative, has said. McCormick is a professor emeritus at UCSF Hellen Diller Family Comprehensive Cancer Center in San Francisco.

The Research Bandwagon

When RAS mutations were initially discovered, there was a flurry of research into new drug possibilities, but these did not lead to effective treatments. Initially, there was hope that farnesyltrans- ferase inhibitors (FTIs) were the answer. However, testing found that, although FTIs did block HRAS, the strategy did not prove effective in phase II trials for lung and pancreatic cancers, or in phase III trials for colorectal and pancreatic cancers.2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication